Perspectives on New Actionable Drivers in NSCLC

Perspectives on New Actionable Drivers in NSCLC is organized by prIME Oncology. This CME Conference has been approved for a maximum of 0.75 AMA PRA Category 1 Credit(s)™.

Dates:
Release Date: Jul 01, 2019
Expiration Date: Jul 01, 2020

Learning Objectives:
After successful completion of this educational activity, participants should be able to:
• Assess the role of broad molecular profiling and the use of liquid biopsy in advanced NSCLC
• Select and evaluate treatment options for patients identified with oncogene drivers such as MET exon 14–skipping mutations or MET amplification, RET, HER2, and NTRK
• Analyze efficacy and safety data of emerging agents in patients harboring new driver mutations and discuss clinical applications of new data
• Explain strategies to overcome acquired resistance to targeted therapy such as EGFR-TKI, including emerging combination targeted-treatment approaches

Additional details will be posted as soon as they are available.